Tags

Type your tag names separated by a space and hit enter

Rapid development of an inactivated vaccine candidate for SARS-CoV-2.
Science. 2020 May 06 [Online ahead of print]Sci

Abstract

The coronavirus disease 2019 (COVID-19) pandemic caused by severe acute respiratory syndrome-coronavirus 2 (SARS-CoV-2) has resulted in an unprecedented public health crisis. There are currently no SARS-CoV-2-specific treatments or vaccines available due to the novelty of the virus. Hence, rapid development of effective vaccines against SARS-CoV-2 are urgently needed. Here we developed a pilot-scale production of a purified inactivated SARS-CoV-2 virus vaccine candidate (PiCoVacc), which induced SARS-CoV-2-specific neutralizing antibodies in mice, rats and non-human primates. These antibodies neutralized 10 representative SARS-CoV-2 strains, suggesting a possible broader neutralizing ability against SARS-CoV-2 strains. Three immunizations using two different doses (3 μg or 6 μg per dose) provided partial or complete protection in macaques against SARS-CoV-2 challenge, respectively, without observable antibody-dependent enhancement of infection. These data support clinical development of SARS-CoV-2 vaccines for humans.

Authors+Show Affiliations

Sinovac Biotech Ltd., Beijing, China.Key Laboratory of Human Disease Comparative Medicine, Chinese Ministry of Health, Beijing Key Laboratory for Animal Models of Emerging and Remerging Infectious Diseases, Institute of Laboratory Animal Science, Chinese Academy of Medical Sciences and Comparative Medicine Center, Peking Union Medical College, Beijing, China.Department of Microbiology, Zhejiang Provincial Center for Disease Control and Prevention, Hangzhou, China.Sinovac Biotech Ltd., Beijing, China.Division of Respiratory Virus Vaccines, National Institute for Food and Drug Control, Beijing, China.CAS Key Laboratory of Infection and Immunity, National Laboratory of Macromolecules, Institute of Biophysics, Chinese Academy of Sciences, Beijing, China.Sinovac Biotech Ltd., Beijing, China.CAS Key Laboratory of Infection and Immunity, National Laboratory of Macromolecules, Institute of Biophysics, Chinese Academy of Sciences, Beijing, China.CAS Key Laboratory of Infection and Immunity, National Laboratory of Macromolecules, Institute of Biophysics, Chinese Academy of Sciences, Beijing, China.CAS Key Laboratory of Infection and Immunity, National Laboratory of Macromolecules, Institute of Biophysics, Chinese Academy of Sciences, Beijing, China.Key Laboratory of Human Disease Comparative Medicine, Chinese Ministry of Health, Beijing Key Laboratory for Animal Models of Emerging and Remerging Infectious Diseases, Institute of Laboratory Animal Science, Chinese Academy of Medical Sciences and Comparative Medicine Center, Peking Union Medical College, Beijing, China.Sinovac Biotech Ltd., Beijing, China.National Institute for Communicable Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Changping, Beijing, China.Sinovac Biotech Ltd., Beijing, China.Key Laboratory of Human Disease Comparative Medicine, Chinese Ministry of Health, Beijing Key Laboratory for Animal Models of Emerging and Remerging Infectious Diseases, Institute of Laboratory Animal Science, Chinese Academy of Medical Sciences and Comparative Medicine Center, Peking Union Medical College, Beijing, China.Sinovac Biotech Ltd., Beijing, China.Sinovac Biotech Ltd., Beijing, China.Sinovac Biotech Ltd., Beijing, China.Institute of Microbiology and Epidemiology, Academy of Military Medical Sciences, Beijing, China.Sinovac Biotech Ltd., Beijing, China.Sinovac Biotech Ltd., Beijing, China.Department of Microbiology, Zhejiang Provincial Center for Disease Control and Prevention, Hangzhou, China.Department of Microbiology, Zhejiang Provincial Center for Disease Control and Prevention, Hangzhou, China.Sinovac Biotech Ltd., Beijing, China.Sinovac Biotech Ltd., Beijing, China.Sinovac Biotech Ltd., Beijing, China.Key Laboratory of Human Disease Comparative Medicine, Chinese Ministry of Health, Beijing Key Laboratory for Animal Models of Emerging and Remerging Infectious Diseases, Institute of Laboratory Animal Science, Chinese Academy of Medical Sciences and Comparative Medicine Center, Peking Union Medical College, Beijing, China.Sinovac Biotech Ltd., Beijing, China.National Institute for Communicable Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Changping, Beijing, China. qinchuan@pumc.edu.cn yjzhang@cdc.zj.cn yinwd@sinovac.com xiangxi@ibp.ac.cn changguili@aliyun.com lujinxing@icdc.cn.Division of Respiratory Virus Vaccines, National Institute for Food and Drug Control, Beijing, China. qinchuan@pumc.edu.cn yjzhang@cdc.zj.cn yinwd@sinovac.com xiangxi@ibp.ac.cn changguili@aliyun.com lujinxing@icdc.cn.CAS Key Laboratory of Infection and Immunity, National Laboratory of Macromolecules, Institute of Biophysics, Chinese Academy of Sciences, Beijing, China. qinchuan@pumc.edu.cn yjzhang@cdc.zj.cn yinwd@sinovac.com xiangxi@ibp.ac.cn changguili@aliyun.com lujinxing@icdc.cn.Sinovac Biotech Ltd., Beijing, China. qinchuan@pumc.edu.cn yjzhang@cdc.zj.cn yinwd@sinovac.com xiangxi@ibp.ac.cn changguili@aliyun.com lujinxing@icdc.cn.Department of Microbiology, Zhejiang Provincial Center for Disease Control and Prevention, Hangzhou, China. qinchuan@pumc.edu.cn yjzhang@cdc.zj.cn yinwd@sinovac.com xiangxi@ibp.ac.cn changguili@aliyun.com lujinxing@icdc.cn.Key Laboratory of Human Disease Comparative Medicine, Chinese Ministry of Health, Beijing Key Laboratory for Animal Models of Emerging and Remerging Infectious Diseases, Institute of Laboratory Animal Science, Chinese Academy of Medical Sciences and Comparative Medicine Center, Peking Union Medical College, Beijing, China. qinchuan@pumc.edu.cn yjzhang@cdc.zj.cn yinwd@sinovac.com xiangxi@ibp.ac.cn changguili@aliyun.com lujinxing@icdc.cn.

Pub Type(s)

Journal Article

Language

eng

PubMed ID

32376603

Citation

Gao, Qiang, et al. "Rapid Development of an Inactivated Vaccine Candidate for SARS-CoV-2." Science (New York, N.Y.), 2020.
Gao Q, Bao L, Mao H, et al. Rapid development of an inactivated vaccine candidate for SARS-CoV-2. Science. 2020.
Gao, Q., Bao, L., Mao, H., Wang, L., Xu, K., Yang, M., Li, Y., Zhu, L., Wang, N., Lv, Z., Gao, H., Ge, X., Kan, B., Hu, Y., Liu, J., Cai, F., Jiang, D., Yin, Y., Qin, C., ... Qin, C. (2020). Rapid development of an inactivated vaccine candidate for SARS-CoV-2. Science (New York, N.Y.). https://doi.org/10.1126/science.abc1932
Gao Q, et al. Rapid Development of an Inactivated Vaccine Candidate for SARS-CoV-2. Science. 2020 May 6; PubMed PMID: 32376603.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Rapid development of an inactivated vaccine candidate for SARS-CoV-2. AU - Gao,Qiang, AU - Bao,Linlin, AU - Mao,Haiyan, AU - Wang,Lin, AU - Xu,Kangwei, AU - Yang,Minnan, AU - Li,Yajing, AU - Zhu,Ling, AU - Wang,Nan, AU - Lv,Zhe, AU - Gao,Hong, AU - Ge,Xiaoqin, AU - Kan,Biao, AU - Hu,Yaling, AU - Liu,Jiangning, AU - Cai,Fang, AU - Jiang,Deyu, AU - Yin,Yanhui, AU - Qin,Chengfeng, AU - Li,Jing, AU - Gong,Xuejie, AU - Lou,Xiuyu, AU - Shi,Wen, AU - Wu,Dongdong, AU - Zhang,Hengming, AU - Zhu,Lang, AU - Deng,Wei, AU - Li,Yurong, AU - Lu,Jinxing, AU - Li,Changgui, AU - Wang,Xiangxi, AU - Yin,Weidong, AU - Zhang,Yanjun, AU - Qin,Chuan, Y1 - 2020/05/06/ PY - 2020/04/10/received PY - 2020/05/02/accepted PY - 2020/5/8/entrez PY - 2020/5/8/pubmed PY - 2020/5/8/medline JF - Science (New York, N.Y.) JO - Science N2 - The coronavirus disease 2019 (COVID-19) pandemic caused by severe acute respiratory syndrome-coronavirus 2 (SARS-CoV-2) has resulted in an unprecedented public health crisis. There are currently no SARS-CoV-2-specific treatments or vaccines available due to the novelty of the virus. Hence, rapid development of effective vaccines against SARS-CoV-2 are urgently needed. Here we developed a pilot-scale production of a purified inactivated SARS-CoV-2 virus vaccine candidate (PiCoVacc), which induced SARS-CoV-2-specific neutralizing antibodies in mice, rats and non-human primates. These antibodies neutralized 10 representative SARS-CoV-2 strains, suggesting a possible broader neutralizing ability against SARS-CoV-2 strains. Three immunizations using two different doses (3 μg or 6 μg per dose) provided partial or complete protection in macaques against SARS-CoV-2 challenge, respectively, without observable antibody-dependent enhancement of infection. These data support clinical development of SARS-CoV-2 vaccines for humans. SN - 1095-9203 UR - https://www.unboundmedicine.com/medline/citation/32376603/full_citation L2 - http://www.sciencemag.org/cgi/pmidlookup?view=long&pmid=32376603 DB - PRIME DP - Unbound Medicine ER -
Try the Free App:
Prime PubMed app for iOS iPhone iPad
Prime PubMed app for Android
Prime PubMed is provided
free to individuals by:
Unbound Medicine.